Shares of Aurobindo Pharma were up 2.09% to Rs 1,072.40 in Monday's session, making it one of the top gainers on the Nifty Midcap 150.
Financial Performance:
Aurobindo Pharma's consolidated financial performance shows consistent growth in revenue and net profit over the years.
Quarterly Performance:
The company's revenue for the quarter-ending June 2025 stood at Rs 7,868.14 Crore, compared to Rs 7,567.02 Crore in June 2024. Net profit for the same period was Rs 822.28 Crore, down from Rs 919.61 Crore in the previous year.
Annual Performance:
The annual revenue for the year-ending March 2025 was Rs 31,723.73 Crore, a significant increase from Rs 29,001.87 Crore in March 2024. The net profit also increased to Rs 3,515.26 Crore in March 2025 from Rs 3,186.13 Crore in March 2024.
The following table summarizes the consolidated quarterly income statement:
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | |
|---|---|---|---|---|---|
| Sales | Rs 7,868 Crore | Rs 8,382 Crore | Rs 7,978 Crore | Rs 7,796 Crore | Rs 7,567 Crore |
| Other Income | Rs 105 Crore | Rs 134 Crore | Rs 157 Crore | Rs 136 Crore | Rs 220 Crore |
| Total Income | Rs 7,973 Crore | Rs 8,516 Crore | Rs 8,135 Crore | Rs 7,932 Crore | Rs 7,787 Crore |
| Total Expenditure | Rs 6,670 Crore | Rs 7,034 Crore | Rs 6,819 Crore | Rs 6,612 Crore | Rs 6,351 Crore |
| EBIT | Rs 1,302 Crore | Rs 1,482 Crore | Rs 1,316 Crore | Rs 1,319 Crore | Rs 1,436 Crore |
| Interest | Rs 97 Crore | Rs 115 Crore | Rs 118 Crore | Rs 112 Crore | Rs 111 Crore |
| Tax | Rs 382 Crore | Rs 432 Crore | Rs 354 Crore | Rs 390 Crore | Rs 405 Crore |
| Net Profit | Rs 822 Crore | Rs 935 Crore | Rs 843 Crore | Rs 816 Crore | Rs 919 Crore |
The following table summarizes the consolidated yearly income statement:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Sales | Rs 31,723 Crore | Rs 29,001 Crore | Rs 24,855 Crore | Rs 23,455 Crore | Rs 24,774 Crore |
| Other Income | Rs 621 Crore | Rs 557 Crore | Rs 290 Crore | Rs 320 Crore | Rs 380 Crore |
| Total Income | Rs 32,345 Crore | Rs 29,559 Crore | Rs 25,145 Crore | Rs 23,775 Crore | Rs 25,155 Crore |
| Total Expenditure | Rs 26,790 Crore | Rs 24,872 Crore | Rs 22,381 Crore | Rs 20,323 Crore | Rs 17,682 Crore |
| EBIT | Rs 5,555 Crore | Rs 4,686 Crore | Rs 2,764 Crore | Rs 3,452 Crore | Rs 7,473 Crore |
| Interest | Rs 457 Crore | Rs 289 Crore | Rs 140 Crore | Rs 48 Crore | Rs 74 Crore |
| Tax | Rs 1,582 Crore | Rs 1,211 Crore | Rs 684 Crore | Rs 725 Crore | Rs 2,009 Crore |
| Net Profit | Rs 3,515 Crore | Rs 3,186 Crore | Rs 1,939 Crore | Rs 2,678 Crore | Rs 5,389 Crore |
The revenue increased by approximately 9.39 percent in 2025 compared to 2024. Similarly, the net profit saw an increase of around 10.34 percent during the same period.
Balance Sheet:
The total assets of Aurobindo Pharma as of March 2025 stood at Rs 49,784 Crore, compared to Rs 45,071 Crore in the previous year. The company's reserves and surplus increased to Rs 32,595 Crore from Rs 29,784 Crore during the same period.
Cash Flow:
The net cash flow from operating activities for the year-ending March 2025 was Rs 3,924 Crore, compared to Rs 2,434 Crore in the previous year. The net cash flow for the same period was Rs 2,178 Crore, compared to -Rs 1,006 Crore in the previous year.
Financial Ratios:
Key financial ratios for Aurobindo Pharma show a P/E ratio of 19.40 and a P/B ratio of 2.06 as of March 2025. The company reported a debt-to-equity ratio of 0.24 as of the year-ending March 2025.
Corporate Actions:
Aurobindo Pharma announced an interim dividend of Rs 4.00 per share on August 4, 2025, with an effective date of August 8, 2025. The company has also undergone bonus issues and stock splits in the past.
Aurobindo Pharma Limited has informed the exchange about copy of newspaper publication on August 20, 2025.
Shares of Aurobindo Pharma were trading with very bearish sentiment, according to Moneycontrol analysis.
With the stock's last traded price at Rs 1,072.40, Aurobindo Pharma has shown positive movement, making it a top gainer on the Nifty Midcap 150.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
